PGK1 contributes to tumorigenesis and sorafenib resistance of renal clear cell carcinoma via activating CXCR4/ERK signaling pathway and accelerating glycolysis

Phosphoglycerate kinase 1 (PGK1) has complicated and multiple functions in cancer occurrence, tumor progression and drug resistance. Sorafenib is the first-line treatment targeted drug for patients with kidney renal clear cell carcinoma (KIRC) as a tyrosine kinase inhibitor, but sorafenib resistance...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Yu, Wang, Xixi, Lu, Weiliang, Zhang, Dan, Huang, Lan, Luo, Yang, Xiong, Li, Li, Haocheng, Zhang, Peng, Li, Qiu, Liang, Shufang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8816910/
https://www.ncbi.nlm.nih.gov/pubmed/35121728
http://dx.doi.org/10.1038/s41419-022-04576-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8816910/
https://www.ncbi.nlm.nih.gov/pubmed/35121728
http://dx.doi.org/10.1038/s41419-022-04576-4

Ejemplares similares